1,706
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

, , , , , , , , , & show all
Pages 850-856 | Received 08 Oct 2015, Accepted 08 Feb 2016, Published online: 30 Mar 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ikram Mezghiche, Hanane Yahia-Cherbal, Lars Rogge & Elisabetta Bianchi. (2021) Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Review of Clinical Immunology 17:4, pages 331-354.
Read now
Jeffrey R. Curtis, Cecilie H. Brahe, Mikkel Østergaard, Merete Lund Hetland, Karen Hambardzumyan, Saedis Saevarsdottir, Xingbin Wang, Darl D. Flake II, Eric H. Sasso & T. W. Huizinga. (2019) Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Current Medical Research and Opinion 35:9, pages 1483-1493.
Read now

Articles from other publishers (12)

Fanni A Meznerics, Lajos V Kemény, Emese Gunther, Eszter Bakó, Fanni Dembrovszky, Bence Szabó, Anna Ascsillán, Elmar Lutz, Dezsö Csupor, Péter Hegyi, András Bánvölgyi & György Nagy. (2023) Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis. Rheumatology 62:6, pages 2048-2059.
Crossref
Kenneth F Baker, Jasmine P X Sim & John D Isaacs. (2021) Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?. The Lancet Rheumatology 3:5, pages e371-e382.
Crossref
Yoshiya Tanaka. (2021) Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. Journal of Clinical Medicine 10:6, pages 1241.
Crossref
Carlos Melus, Brenden Rossin, Mary Ann Aure & Michael Mahler. 2021. Precision Medicine and Artificial Intelligence. Precision Medicine and Artificial Intelligence 65 96 .
Tate M. Johnson, Kaleb Michaud & Bryant R. England. (2020) Measures of Rheumatoid Arthritis Disease Activity. Arthritis Care & Research 72:S10, pages 4-26.
Crossref
Tate M. Johnson, Kyle A. Register, Cynthia M. Schmidt, James R. O'Dell, Ted R. Mikuls, Kaleb Michaud & Bryant R. England. (2019) Correlation of the Multi‐Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta‐Analysis. Arthritis Care & Research 71:11, pages 1459-1472.
Crossref
Melanie Hagen, Matthias Englbrecht, Judith Haschka, Michaela Reiser, Arnd Kleyer, Axel Hueber, Bernhard Manger, Camille Figueiredo, Jayme Fogagnolo Cobra, Hans-Peter Tony, Stephanie Finzel, Stefan Kleinert, Jörg Wendler, Florian Schuch, Monika Ronneberger, Martin Feuchtenberger, Martin Fleck, Karin Manger, Wolfgang Ochs, Hans-Martin Lorenz, Hubert Nüsslein, Rieke Alten, Jörg Henes, Klaus Krüger, Georg Schett & Jürgen Rech. (2019) Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. The Journal of Rheumatology 46:5, pages 460-466.
Crossref
Jeffrey R. Curtis, Fenglong Xie, Shuo Yang, Maria I. Danila, Justin K. Owensby & Lang Chen. (2019) Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States. The Journal of Rheumatology 46:3, pages 237-244.
Crossref
Nadia M. T. Roodenrijs, Maria J. H. de Hair, Gill Wheater, Mohsen Elshahaly, Janneke Tekstra, Y. K. Onno Teng, Floris P. J. G. Lafeber, Ching Chang Hwang, Xinyu Liu, Eric H. Sasso & Jacob M. van Laar. (2018) The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. Arthritis Research & Therapy 20:1.
Crossref
Gary M Oderda, Grant D Lawless, Grace C Wright, Samuel R Nussbaum, Renwyck Elder, Kibum Kim & Diana I Brixner. (2018) The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. Personalized Medicine 15:4, pages 291-301.
Crossref
Sonja Stojanovic, Bojana Stamenkovic, Tatjana Jevtovic Stoimenov, Jovan Nedovic, Valentina Zivkovic, Milena Despotovic & Dusica Pavlovic. (2017) Association of tumor necrosis factor–α (G-308A) genetic variant with matrix metalloproteinase–9 activity and joint destruction in early rheumatoid arthritis. Clinical Rheumatology 36:7, pages 1479-1485.
Crossref
Jeffrey R. Curtis, Grace C. Wright, Vibeke Strand, Charles S. Davis, Elena Hitraya & Eric H. Sasso. (2017) Reanalysis of the Multi‐Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. Arthritis & Rheumatology 69:4, pages 863-865.
Crossref